AstraZeneca's portfolio spans oncology, respiratory and immunology, and cardiovascular, renal and metabolic diseases. Tagrisso remains a key commercial product, alongside Tezspire and Baxfendy, while recent clinical and regulatory developments highlight continued portfolio expansion.

Biogen's portfolio includes established commercial products as well as newer pipeline developments. TYSABRI remains an important part of its neuroscience portfolio, while EMPAVELI/ASPAVELI represents another commercial product in PNH. At the same time, litifilimab is advancing through Phase III development in cutaneous lupus erythematosus, alongside recent clinical developments across the company's pipeline. er you need it.

Tax free

Benefit from tax-free shopping, simplifying your purchase and enhancing your savings without any extra costs.